Home Tags Metastatic triple-negative breast cancer

Tag: metastatic triple-negative breast cancer

Sacituzumab Govitecan Approved in China for Second-Line Metastatic Triple-Negative Breast Cancer

China's National Medical Products Administration (NMPA) has approved sacituzumab govitecan (Trodelvy®; Gilead Sciences) for the treatment of adult patients with unresectable locally advanced or metastatic...

Sacituzumab Govitecan Receives European Marketing Authorization for the Treatment of mTNBC...

The European Commission (EC) has granted marketing authorization for sacituzumab govitecan (Trodelvy®; Gilead Sciences) a first-in-class topoisomerase inhibitor antibody-drug conjugate (ADC) directed to the...
ESMO 2017 - 3

ESMO 2020: Sacituzumab Govitecan Shows Encouraging Early-Stage Clinical Results in Brain...

A clinical trial (NCT03995706) studying the extent by which sacituzumab govitecan (Trodelvy™; Immunomedics) is able to get into the brain and treat patients with...

Everest Medicines’ Licensing Partner Immunomedics Receives FDA Accelerated Approval for Sacituzumab...

Everest Medicines' U.S.-based licensing partner Immunomedics earlier today confirmed that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA)...

Ladiratuzumab Vedotin (SGN-LIV1A) in Triple Negative Breast Cancers Shows a 29%...

Updated data from an ongoing Phase I clinical trial evaluating ladiratuzumab vedotin (SGN-LIV1A) in patients with metastatic triple negative breast cancer (mTNBC), was presented...

SGN-LIV1A Monotherapy Data Show 37% ORR in Heavily Pretreated Triple Negative...

Data from an ongoing phase I clinical trial evaluating SGN-LIV1A for patients with metastatic breast cancer (MBC), with particular focus on metastatic triple-negative breast...

X